GeneDx Holdings Corp. (NASDAQ:WGS – Get Free Report)’s share price was down 7.4% on Tuesday. The company traded as low as $47.59 and last traded at $47.22. 116,062 shares traded hands during mid-day trading, a decline of 88% from the average session volume of 936,615 shares. The stock had previously closed at $51.02.
Analyst Ratings Changes
A number of analysts have issued reports on the company. BTIG Research reaffirmed a “buy” rating and set a $85.00 price target (down from $90.00) on shares of GeneDx in a report on Tuesday, November 10th. Canaccord Genuity Group increased their price objective on GeneDx from $75.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. Guggenheim boosted their target price on GeneDx from $74.00 to $83.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Wall Street Zen raised GeneDx from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Zacks Research lowered shares of GeneDx from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 9th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, GeneDx has a consensus rating of “Moderate Buy” and a consensus target price of $90.14.
Check Out Our Latest Stock Analysis on WGS
GeneDx Stock Performance
The firm has a fifty day simple moving average of $73.13 and a 200-day simple moving average of $69.98. The company has a quick ratio of 3.06, a current ratio of 4.16 and a debt-to-equity ratio of 0.60. The company has a market cap of $1.35 billion, a PE ratio of -11.99 and a beta of 2.00.
GeneDx (NASDAQ:WGS – Get Free Report) last posted its earnings results on Monday, November 9th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.07 by $0.21. The business had revenue of $123.10 million during the quarter, compared to the consensus estimate of $122.93 million. GeneDx had a positive return on equity of 1.98% and a negative net margin of 24.10%. During the same period in the previous year, the business earned ($0.27) EPS. On average, research analysts forecast that GeneDx Holdings Corp. will post -0.41 EPS for the current fiscal year.
Insider Buying and Selling
In other GeneDx news, CEO Katherine Stueland sold 10,501 shares of the firm’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $97.61, for a total transaction of $1,025,002.61. Following the transaction, the chief executive officer directly owned 115,476 shares of the company’s stock, valued at approximately $11,271,612.36. This trade represents a 8.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Kevin Feeley sold 3,728 shares of the firm’s stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $97.61, for a total transaction of $363,890.08. Following the transaction, the chief financial officer directly owned 44,945 shares in the company, valued at $4,387,081.45. The trade was a 7.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 19,206 shares of company stock worth $1,808,056. Insiders own 25.17% of the company’s stock.
Institutional Trading of GeneDx
A number of hedge funds have recently added to or reduced their stakes in WGS. Fifth Third Bancorp purchased a new position in shares of GeneDx in the 1st quarter valued at approximately $31,000. Nykredit A S purchased a new stake in shares of GeneDx during the second quarter worth approximately $38,000. Sterling Capital Management LLC lifted its holdings in shares of GeneDx by 851.4% during the third quarter. Sterling Capital Management LLC now owns 666 shares of the company’s stock worth $48,000 after purchasing an additional 596 shares during the period. Calamos Advisors LLC acquired a new stake in shares of GeneDx during the third quarter worth $225,000. Finally, AlphaGrep UK Ltd acquired a new stake in shares of GeneDx during the second quarter worth $238,000. 61.72% of the stock is owned by institutional investors and hedge funds.
About GeneDx
GeneDx is a genomic testing company focused on helping clinicians diagnose rare and inherited conditions. Its services include whole exome and whole genome sequencing, along with other genetic tests and clinical interpretation of results. The company’s testing is used by healthcare providers to support diagnosis and care decisions, particularly for patients with suspected rare genetic disorders. GeneDx also offers testing related to hereditary cancer risk. Founded in 2000 by researchers with experience at the National Institutes of Health, GeneDx has developed its business around applying genomic information in clinical care.
See Also
- Five stocks we like better than GeneDx
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.
